CV Prof. Dr. Michael Schmitt - Hämatologie und Onkologie Rostock

onkologie.rostock.de

CV Prof. Dr. Michael Schmitt - Hämatologie und Onkologie Rostock

Curriculum vitae Prof. Dr. med. Michael Schmitt 1

CURRICULUM VITAE Michael Schmitt


Curriculum vitae Prof. Dr. med. Michael Schmitt 2

Name:

Prof. Dr. med. Michael Schmitt

Geburtsdatum:

11.10.1966 in Neunkirchen/Saar

Curriculum Vitae

Dienstanschrift:

Leiter der Klinischen Stammzelltransplantation und Immuntherapie

Medizinische Klinik III

Zentrum für Innere Medizin

Universitätsklinikum Rostock

Ernst-Heydemann-Str. 6

18057 Rostock

Tel.: ++49 –381-494-7424

Fax: ++49 –381-494-7422

E-Mail: michael.schmitt@med.uni-rostock.de

Homepage: www.onkologie-rostock.de/htdocs/immuntherapie.html

Privatanschrift:

Hohen Stein 17

18198 Kritzmow

Tel.: ++49 –38207-775-404

Fax: ++49 –38207-775-393

E-mail: michael.schmittu@t-online.de

Nationalität: Deutsch.

Familienstand: Verheiratet mit Dr. Anita Schmitt, Fachärztin für Transfusionsmedizin.

Zwei Söhne, Matthias (*2002) und Johannes (*2004).

Universitätsausbildung:

01/2010

09/2009

05/2009

seit 01/2009

Master of Business Health Administration (MBHA); Abschluss eines

viersemestrigen berufsbegleitenden Studiums an der Universität

Nürnberg-Erlangen

Koordinator des EU-Antrages „SCALA – Specific Cellular Anti-Leukemia

Antigen Therapies for Patients with Hematological Malignancies”

im 7. Rahmenprogramm der EU

Umhabilitation durch die Medizinische Fakultät der Universität Rostock

für das Fach Innere Medizin

Leiter der Klinischen Stammzelltransplantation und Immuntherapie,

Oberarzt der Medizinischen Klinik III, Zentrum für Innere

Medizin (Ärztl. Dir.: Prof. M. Freund), Universitätsklinikum Rostock

07/2008 Erlangung der Schwerpunktbezeichnung Infektiologie

05/2008 Gastprofessor an der Medizinischen Universität Lublin, Polen

01/2008 Sachkundige Person für Impfstoffherstellung nach §15 AMG

12/2006 Apl. Professor für Innere Medizin an der Universität Ulm


Curriculum vitae Prof. Dr. med. Michael Schmitt 3

08/2005 Erwerb der Gebietsbezeichnung für Hämatologie/Internistische Onkologie

03/2004 Erlangung der Venia legendi für das Fach Innere Medizin

Thema der Habilitationsschrift: „Identifikation von immunogenen Antigenen

bei der akuten myeloischen Leukämie zur Entwicklung einer

Tumorvakzine“.

12/2003 Facharzt für Innere Medizin

10/2006 - 12/2008 Mitglied des Promotionsausschusses der Medizinischen Fakultät der

Universität Ulm

01/2004 - 12/2008 Stationsarzt der Stammzell-Transplantationseinheit

(Leiter des Transplantations-Programms: Prof. Dr. D. Bunjes)

04/1998 – 12/2008 Leiter des Tumor-Immunologie-Labors in der Klinik für Innere

Medizin III des Universitätsklinikums Ulm, (Komm. Ärztl. Dir.: Prof.

Dr. L. Bergmann, seit 09/99 Ärztl. Dir.: Prof. Dr. H. Döhner)

04/95 - 03/98 Research Fellow in der II. Med. Klinik (Hämatologie/Onkologie) der

Universität Mie, Tsu, Japan (Dir.: Prof. Dr. H. Shiku), Stipendiat des

Science and Technology Fellowship Program STF 10 der Europäischen

Kommission

03/94 - 04/95 Research Fellow in der Abteilung für Experimentelle Onkologie an

der Universität Nagasaki (Dir.: Prof. Dr. H. Shiku), Stipendiat des

Special Exchange Program SEP des Japanisch-Deutschen Zentrums

Berlin

12/93 - 03/94 Assistenzarzt in der I. Med. Klinik der Universitätskliniken Homburg

/Saar (Dir.: Prof. Dr. M. Pfreundschuh)

12/93 Approbation zum Arzt

06/92 - 11/93 Arzt im Praktikum (AiP) in der I. Med. Klinik der Universitätskliniken

Homburg/Saar (Dir.: Prof. Dr. M. Pfreundschuh)

11/92 Promotion zum Dr. med., Dissertation mit dem Thema „Gleichzeitige

Bestimmung neuer Parameter des Eisenstoffwechsels und der

Erythrozytenüberlebenszeit“ (Doktorvater: Prof. Dr. B. Berberich)

05/92 Staatsexamen

1991 Elective Student an der Harvard Medical School, Boston, MA, USA

(Hematology/Oncology, Prof. Mortimer Greenberg, Mt. Auburn Hospital,

Endocrinology/Metabolism, Prof. Gordon C. Weir, Joslin Diabetes

Center, Cardiology, Prof. Peter V. Tishler, VAMC Boston)

1989 Sommersemester an der Universität Tel-Aviv, Tel-Aviv, Israel (Gynäkologie

bei Prof. Dr. C. Sakut)

1987-88 Leiter der Fachschaft Medizin im Cusanuswerk

10/85 Beginn der Studien der Humanmedizin und der Orientalistik an der

Universität des Saarlandes


Curriculum vitae Prof. Dr. med. Michael Schmitt 4

Erfahrungen in der Klinischen Prüfung

seit 1992 Prüfarzt in verschiedenen Klinischen Phase I, II und III – Prüfstudien

für Patienten mit M. Hodgkin, Nierenzellkarzinom, Akuter Myeloischer

Leukämie, Myelodysplastischem Syndrom, Multiplem Myelom

oder Chronisch Lymphatischer Leukämie

10/2008 Teilnahme an einer GCP-Schulung mit Zertifikat

Mitgliedschaften:

- European Society for Cancer Immunology and Immunotherapy seit 2006

- Verein für Krebsimmuntherapie e.V. (KIMT) seit 2003

- European Organisation for Research and Treatment of Cancer (EORTC) seit 2000

- American Association for Cancer Research (AACR) seit 1999

- American Society for Hematology (ASH) seit 1998

- Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) seit 1997

- Gesellschaft deutscher Naturforscher und Ärzte (GDNÄ) seit 1987

Stipendien:

- Science and Technology Fellow (STF) der Europäischen Kommission 1996-98

- Fellow des Special Exchange Program des Japanisch-Deutschen Zentrums Berlin 1994-95

- Stipendiat der Studienstiftung des deutschen Volkes 1987-92

- Stipendiat des Cusanuswerkes 1987-92

Gutachtertätigkeit:

- Deutsche Krebshilfe

- Fonds für die Förderung der wissenschaftlichen Forschung (FWF; Österreich)

- UK Cancer Research Fund

- Mitglied der Jury des „Kuwait Price of Immunology” (= „Nobelpreis der arab. Welt“)

- Journal of Clinical Investigation

- Blood

- Cancer Immunity

- Cancer Immunology and Immunotherapy

- Clinical Cancer Research

- Leukemia

- Leukemia and Lymphoma

Patente:

02/2006 DE-Patent Nr.: 102006 005827.5 „mRNA Transfektion von adulten

Progenitorzellen zur spezifischen Gewebsregeneration”

09/2003 US-Patent No.: US 2003/0170755 A1 „Tumor-associated antigen

RHAMM“

Preise:

- Hans-Jochen Illiger-Gedächtnispreis 2008

- Feliks-Skubiszewski-Medaille der Medizinischen Universität Lublin 2005

- Novartis-Preis 1999

Sprachen:

Deutsch, Englisch, Französisch, Japanisch, Italienisch, Hebräisch, Latein, Spanisch.

Rostock, im Januar 2010

Prof. Dr. med. Michael Schmitt


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

Publikationsverzeichnis

Michael Schmitt


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

Chronologisches Verzeichnis der Publikationen 1997-2010:

ORIGINALBARBEITEN

1. Schmitt M, Ikeda H, Nagata Y, Gu X, Wang L, Kuribayashi K, Shiku H. Involvement of T-

cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma

cells transfected with interleukin-12 (IL-12) genes. Int J Cancer 72: 505-511, 1997.

IF: 4,734

2. Gu X, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki Y, Akiyoshi K, Sunamoto J,

Nakamura H, Kuribayashi K, Shiku H. A novel hydrophobized polysaccharide/ oncoprotein

complex vaccine induces in vitro and in vivo cellular and humoral immune responses

against HER2-expressing murine sarcomas. Cancer Res 58: 3385-3390, 1998.

IF: 7,514

3. Wang L, Ikeda H, Ikuta Y, Schmitt M, Miyahara Y, Takahashi Y, Gu X, Nagata Y, Sasaki

Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K, Shiku H. Bone marrow-derived

dendritic cells incorporate and process hydrophobized polysaccharide/ oncoprotein

complex as antigen presenting cells. Int J Oncol 14: 695-701, 1999.

IF: 2,234

4. Itoh M, Watanabe M, Yamada Y, Furukawa K, Taniguchi M, Hata T, Schmitt M, Ikeda H,

Yamaguchi M, Ohno T, Nakashima K, Shiku H. HUB1 is an autoantigen frequently eliciting

humoral immune response in patients with adult T cell leukemia. Int J Oncol 14: 703-708,

1999.

IF: 2,234

5. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U,

Bergmann L, Schmitt M. Simultaneous expression of different immunogenic antigens in

acute myeloid leukemia. Exp Hematol 28: 1413-1422, 2000.

IF: 3,203

6. Ringhoffer M, Schmitt M, Karbach J, Jäger E, Oesch F, Arand M. Quantitative

assessment of the expression of melanoma-associated antigens by non-competitive

reverse transcription polymerase chain reaction. Int J Oncol 19: 983-989, 2001.

IF: 2,234


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

7. Schmitt M, Taniguchi M, Yoshida Y, Miyahara Y, Gu X, Mukai K, Yagita H, Döhner H,

Shiku H. Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone

marrow transplantation: reminiscence of gut-associated acute graft-versus-host reaction.

Int J Oncol 21: 795-801, 2002.

IF: 2,234

8. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V,

Gschwend J, Bergmann L, Döhner H, Schmitt M. Receptor for hyaluronan acid-mediated

motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and

chronic myeloid leukemia. Exp Hematol 30: 1029-1035, 2002.

IF: 3,203

9. Schneckenburger H, Hendinger A, Sailer R, Strauss WSL, Schmitt M. Laser-assisted

optoporation of single cells. J Biomed Optics 7: 410-416, 2002.

IF: 3,084

10. Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M, Gu X, Watanabe M,

Akiyoshi K, Nakamura H, Kuribayashi K, Sunamoto J, Shiku H. Presentation of a major

histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells

incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications

for a polyvalent immuno-cell therapy. Blood 99: 3717-3724, 2002.

IF: 10,432

11. Schmitt A, Reinhardt P, Schmitt M, Nowak-Harnau S, Maccari B, Schulz A, Kubanek B,

Wiesneth M. Functional state of steroid- versus G-CSF-mobilized granulocytes:

Considerations about the storage of granulocyte concentrates for neutropenic patients.

Transfus Med Hemother 29: 57-64, 2002.

IF: 0,491

12. Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Döhner H,

Schmitt M. Expression of human leucocyte antigens and costimulatory molecules on

blasts of patients with acute myeloid leukaemia. Brit J Haematol 120: 1000-1008, 2003.

IF: 4,478

13. Li L, Schmitt A, Reinhardt P, Greiner J, Ringhoffer M, Vaida B, Bommer M, Vollmer M,

Wiesneth M, Döhner H, Schmitt M. Reconstitution of CD40 and CD80 in dendritic cells

generated from blasts of patients with acute myeloid leukemia. Cancer Immun 3: 8, 2003.

IF: not yet listed

14. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M.


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

Characterization of several leukemia-associated antigens inducing humoral immune

responses in acute and chronic myeloid leukemia (AML/CML). Int J Cancer 106: 224-231,

2003.

IF: 4,734

15. Haerter G, Manfras BJ, de Jong-Hesse Y, Wilts H, Mertens T, Kern P, Schmitt M.

Cytomegalovirus retinitis in a patient treated with anti–tumor necrosis factor alpha antibody

therapy for rheumatoid arthritis. Clin Infect Dis 39:88-94, 2004.

IF: 8,266

16. Greiner J, Wiehe J, Wiesneth M, Zwaka TP, Prill T, Schwarz K, Bienek-Ziolkowski M,

Schmitt M, Döhner H, Hombach V, Torzewski J. Transient genetic labeling of human

CD34 positive hematopoietic stem cells using nucleofection. Transfus Med Hemother 31:

136-141, 2004.

IF: 0,491

17. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Döhner H,

Riechelmann H, Wiesneth M, Gronau S. Opsonization with a trifunctional bispecific (αCD3

x αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor

cells by cytotoxic T lymphocytes. Int J Onc 25: 841-848, 2004.

IF: 2,234

18. Ringhoffer M, Müller CR, Schenk A, Kirsche H, Schmitt M, Greiner J, Döhner H,

Gschwend JE. Simultaneous expression of T cell activating antigens in renal cell

carcinoma: Implications for specific immunotherapy. J Urol 171: 2456-2460, 2004.

IF: 9,952

19. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Shiku H, Döhner H, Schmitt M. mRNA

expression for leukemia-associated antigens in patients with acute myeloid leukemia for

the development of specific immunotherapies. Int J Cancer 108: 704-711, 2004.

IF: 4,734

20. Li L, Reinhardt P, Schmitt A, Barth TFE, Greiner J, Ringhoffer M, Döhner H, Wiesneth M,

Schmitt M. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain

the expression of immunogenic leukemia associated antigens. Cancer Immunol

Immunother 54:685-693, 2005.

IF: 3,804

21. Gronau S, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H.

Trifunctional bispecific antibodies induce tumor cell lysis of squamous cell carcinomas of


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

the upper aerodigestive tract. Head Neck 27:376-582, 2005.

IF: 2,603

22. Gronau S, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H.

Removab® aktivierte Lymphozyten bei Plattenepithelkarzinomen des oberen Aerodigestiv-

traktes. / T-cells Activated with a Trifunctional Bispecific Antibody in Head and Neck

Cancer. Laryngorhinootologie 84:822-828, 2005. [in German]

IF: 0,373

23. Giannopoulos K, Dmoszyńska A, Roliński J, Hus I, Schmitt M. The expression of survivin

in patients with B-cell chronic lymphocytic leukemia (B-CLL). Acta Haematologica Polonica

36: 83-88, 2005.

IF: not yet listed

24. Greiner J, Li L, Ringhoffer M, Barth T, Wiesneth M, Döhner H, and Schmitt M.

Identification and characterization of epitopes of the receptor for hyaluronic acid mediated

motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients

with acute myeloid leukemia. Blood 106:938-945, 2005.

IF: 10,432

25. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K,

Dmoszyńska A, Schmitt M. Allogeneic dendritic cells pulsed with tumor lysates or

apoptotic bodies as immunotherapy for patients with early stage B-cell chronic lymphocytic

leukemia (B-CLL). Leukemia 19:1621-7, 2005.

IF: 8,634

26. Chen BA, Bi YZ, Ding JH, Zhang Y, Gao C, Sun YY, Zhao G, Wang J, Cheng J, Sun XM,

Schmitt M, Döhner H. Induction of immune tolerance for allogeneic recipient mice by non-

myeloablative bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi (J Exp

Hematol) 13:1054-7, 2005. [in Chinese]

IF: not yet listed

27. Gronau S, Thess B, Riechelmann H, Fischer Y, Schmitt A, Schmitt M. An autologous

system for culturing head and neck squamous cell carcinomas for the assessment of

cellular therapies on the chorioallantois membrane. Eur Arch Otorhinolaryngol 263:308-

312, 2006.

IF: 0,843

28. Li L, Giannopoulos K, Reinhardt P, Schmitt A, Greiner J, Roliński J, Hus I, Dmoszyńska A,


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

Döhner H, Wiesneth M and Schmitt M. Immunotherapy for patients with acute myeloid

leukemia using autologous dendritic cells generated from leukemic blasts. Int J Onc.

28:855-861, 2006.

IF: 2,234

29. Hus I, Podhorecka M, Bojarska-Junak A, Roliński J, Schmitt M, Sieklucka M, Wąsik-

Szczepane E, Dmoszyńska A. The clinical significance of ZAP-70 and CD38 expression in

B-cell chronic lymphocytic leukaemia. Ann Oncol. 174:683-690, 2006.

IF: 4,935

30. Giannopoulos K, Li L, Bojarska-Junak A, Roliński J, Dmoszyńska A , Hus I , Greiner J,

Renner C, Döhner H, Schmitt M. Expression of RHAMM/CD168 and other tumor

associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Onc 29:95-

103, 2006.

IF: 2,234

31. Giannopoulos K, Schmitt M. Targets and strategies for T cell based vaccines in patients

with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 47:2028-2036, 2006.

IF: 1,939

32. Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Döhner K, Döhner H, Greiner J.

Chronic myeloid leukemia (CML) cells express tumor associated antigens eliciting specific

CD8+ T cell responses and are lacking costimulatory molecules. Exp Hematol 34:1709-

1719, 2006.

IF: 3,203

33. Greiner J*, Schmitt M*, Li L, Giannopoulos K, Bösch K, Döhner K, Schlenk RF, Pollack

JR, Döhner H, Bullinger L. Expression of tumor-associated antigens (TAAs) in acute

myeloid leukemia (AML): implications for specific immunotherapeutic approaches. Blood

108:4109-4117, 2006. (*both authors contributed equally)

IF: 10,432

34. Wiehe J, Niesler C, Torzewski J, Zimmermann O, Wiesneth M, Schmitt M, Schwarz K,

Döhner H, Hombach V, Greiner J. Efficient transient genetic labeling of human CD34+

progenitor cells for in vivo application. Regenerative Med 1:223-234, 2006.

IF: 1,183

35. Giannopoulos K, Dmoszyńska A, Wlasiuk P, Roliński J, Bojarska-Junak A, Hus I, Schmitt

M. Increased frequency of T regulatory cells in patients with early stage of B-cell chronic


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

lymphocytic leukemia (B-CLL). Acta Haematol Polonica 37:80-85, 2006. [in Polish]

IF: not yet listed

36. Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J,

Guillaume P, Dohner H, Bunjes D, Schmitt M. Imatinib impairs CD8+ T lymphocytes

specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.

Cancer Immunol Immunother 56:849-861, 2007.

IF: 3,804

37. Ringhoffer M, Harsdorf SV, Schmitt M, Wiesneth M, Zenz T, Stilgenbauer S, Greiner J,

Döhner K, Marx M, Döhner H, Bunjes D. Reduced-intensity conditioning followed by T-cell

depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia

and minimal residual disease at the time of transplant: high risk of molecular relapse. Br J

Haematol 136:127-130, 2007.

IF: 4,478

38. Chen J, Schmitt A, Bunjes D, Chen B, Schmitt M. The receptor for hyaluronic acid-

mediated motility induces specific CD8+ T cell response in healthy donors and patients

with chronic myeloid leukemia after allogeneic stem cell transplantation. Int J Onc

30:1119-1127, 2007.

IF: 2,234

39. Britten CM, Gouttefangeas C, Schoenmaekers-Welters MJP, Pawelec G, Koch S,

Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Mackensen A, Haas

I, Svane IM, Hadrup SR, Straten PT, Schmitt M, Giannopoulos K, Maier R, Veelken H,

Bertinetti C, Konur A, Stevanovic S, Wölfel T, van der Burg SH. The CIMT Monitoring

Panel: Enumeration of antigen-specific CD8+ T lymphocytes by structural and functional

assays. 4th CIMT Annual Meeting: Cancer Immunol Immunother 56:406-407, 2007.

IF: 3,804

40. Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, Schroen

C, Atz J, Schmitt M. Adoptive therapy of head and neck squamous carcinoma with

antibody coated immune cells – a pilot clinical trial. Cancer Immunol Immunother 56:1397-

1406, 2007.

IF: 3,804

41. Chen BA, Dong WM, Ding JH, Sun XM, Deng XJ, Zhang Y, Bi YZ, Zhao G, Gao C, Sun


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

YY, Wang J, Cheng J, Schmitt M, Schmitt A. Selective Elimination of Alloreactive Donor

Lymphocytes by Using TBI and Cyclophosphamide. Zhongguo Shi Yan Xue Ye Xue Za Zhi

15:332-336, 2007. (in Chinese)

IF: not yet listed

42. Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Döhner H, Bunjes D, Schmitt

M. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a

dose-dependent manner. Int J Oncol 31:1133-1139, 2007.

IF: 2,234

43. Schmitt A, Reinhardt P, Hus I, Tabarkiewicz J, Roliński J, Giannopoulos K, Dmoszyńska A,

Wiesneth M, Schmitt M. Large-scale generation of autologous dendritic cells for

immunotherapy in patients with acute myeloid leukemia. Transfusion 47:1588-1594, 2007.

IF: 3,475

44. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M, Roliński J,

Dmoszyńska A. The high frequency of T regulatory cells in patients with B-cell chronic

lymphocytic leukemia (B-CLL) is diminished through treatment with thalidomide. Leukemia

22:222-224, 2008.

IF: 8,634

45. Schmitt M, Schmitt A, Rojewski M, Chen J, Götz M, Heyduk M, Giannopoulos K, Ritter G,

Gnjatic S, Guillaume P, Ringhoffer M, Schlenk R, Liebisch P, Bunjes D, Shiku H, Döhner

H, Greiner J. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia,

myelodysplastic syndrome and multiple myeloma elicits immunological and clinical

responses. Blood 111:1357-1365, 2008.

IF: 10,432

46. Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M, Schmitt M.

Quantitative expression of Toll-like receptor-2, -4 and -9 in dendritic cells generated from

blasts of patients with acute myeloid leukemia. Transfusion 48:861-870, 2008.

IF: 3,475


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

47. Chen J, Schmitt A, Chen B, Rojewski M, Rüßeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von

Harsdorf S, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M. Nilotinib

hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell

receptor signaling. J Cell Mol Med 12: 2107-2118, 2008.

IF: 5,114

48. Yao J, Bechter C, Wiesneth M, Götz M, Germeroth L, Guillaume P, von Harsdorf S,

Mertens T, Michel D, Döhner H, Bunjes D, Schmitt M, Schmitt A. Multimer staining of

CMVpp65 specific T cells for diagnosis and therapeutic purpose - a comparative study.

Clin Infect Dis 46:96-105, 2008.

IF: 8,266

49. Hus I*, Schmitt M*, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos

K, Dmoszyńska A, Roliński J. Vaccination of B-CLL patients with autologous dendritic cells

can change the frequency of leukemia antigen-specific CD8+ T cells as well as

CD4+CD25+FoxP3+ regulatory T cells towards an anti-leukemia response. Leukemia

22:1007-1017, 2008. (*both authors contributed equally)

IF: 8,634

50. Giannopoulos K, Dmoszyńska A, Bojarska-Junak A, Schmitt M, Roliński J. Expression of

HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem

Cytobiol 46:457-460, 2008.

IF: 0,886

51. Giannopoulos K, Schmitt M, Kowal M, Własiuk P, Bojarska-Junak A, Roliński J,

Dmoszyńska A. The significance of soluble HLA-G plasma levels as well as messenger

HLA-G are not prognostic factors for B-cell chronic lymphocytic leukemia (B-CLL). Leuk

Res 32:1815-1819, 2008.

IF: 2,390

52. Giannopoulos K, Schmitt M, Własiuk P, Bojarska-Junak A, Chocholska S, Tomczak W,

Roliński J, Dmoszyńska A. High frequency of Th17 T cells in B-cell chronic lymphocytic

leukemia. Acta Haemat Pol 39:237-244, 2008.

IF: not yet listed


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

53. Giannopoulos K, Schmitt M, Kowal M, Własiuk P, Bojarska-Junak A, Chen J, Roliński J,

Dmoszyńska A. Characterization of T regulatory cells in patients with B-cell chronic

lymphocytic leukemia (B-CLL). Oncol Reports 20:677-82, 2008.

IF: 1,524

54. Chen BA, Deng XJ, Ding JH, Sun XM, Dong WM, Bi YZ, Zhang Y, Zhao G, Gao C, Sun

YY, Wang J, Cheng J, Ma Y, Song HH, Bao W, Schmitt A, Schmitt M. Effect of recipient

mouse splenocytes taken orally by donor mouse on GVHD after splenocyte

transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16:126-130, 2008. Chinese.

IF: not listed

55. Fei F * , Yu Y * , Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J,

Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M. Dasatinib exerts an

immunosuppressive effect on CD8 + T cells specific for viral and leukemia antigens. Exp

Hematol 36:1297-1308, 2008. (*both authors contributed equally)

IF: 3,203

56. Hus I, Kawiak J, Tabarkiewicz J, Radej S, Hoser G, Bojarska-Junak A, Schmitt M,

Giannopoulos K, Dmoszyńska A, Roliński J. Immunotherapy with irradiated autologous

leukemic cells in patients with B-CLL in early stages. Oncology Reports 20:443-51, 2008.

IF: 1,524

57. Greiner J, Guinn B, Döhner H, Bullinger L, Schmitt M. Leukemia-associated antigens

(LAAs) are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res

14:1-6, 2008.

IF: 6,488

58. Maxeiner H, Rojewski M, Schmitt A, Tumani H, Bechter K, Schmitt M. Flow cytometric

analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood

from patients with neurological and psychiatric disorders. Brain, Behavior, and Immunity

23:134-142, 2009.

IF: 4,909

59. Fei F*, Yu Y*, Schmitt A, Rojewski M, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M.

Dasatinib inhibits the proliferation and function of CD4 + CD25 + regulatory T cells. Brit J

Hematol 144:195-205, 2009. (*both authors contributed equally)

IF: 4,478


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

60. Guinn* B, Greiner* J, Schmitt M, Mills KI. Elevated expression of the leukaemia

associated antigen SSX2IP predicts good survival in acute myeloid leukaemia patients

who lack detectable cytogenetic rearrangements. Blood 113:1203-1204, 2009. (*both

authors contributed equally) (Letter)

IF: 10,432

61. Schmitt A, Barth T, Beyer E, Borchert F, Rojewski M, Chen J, Guillaume P, Gronau S,

Greiner J, Möller P, Riechelmann H, Schmitt M. The tumor antigens RHAMM and

G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific

CD8+ T cell responses. Int J Oncol 34:629-639, 2009.

IF: 2,234

62. Giannopoulos K, Mertens D, Buehler A, Barth TFE, Idler I, Möller P, Kröber A, Greiner J,

Chocholska S, Dmoszyńska A, Roliński J, Döhner H, Stilgenbauer S, Schmitt M. The

candidate immunotherapeutical target receptor for hyaluronic acid mediated motility

(RHAMM) is associated with proliferation and shows prognostic value in B-cell chronic

lymphocytic leukemia. Leukemia 23:519-527, 2009.

IF: 8,634

63. Schmitt A*, Bechter C*, Yao J, Goetz M, Maccari B, Schauwecker P, Wiesneth M, Schmitt

M. Cytomegalovirus vaccination of leukemia and lymphoma patients after allogeneic stem

cell transplantation--validation of a peptide vaccine. J Immunol Methods 343:140-147,

2009. (*both authors contributed equally)

IF: 2,120

64. Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L,

Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M. RHAMM (CD168) is

overexpressed at the protein level and may constitute an immunogenic antigen in

advanced prostate cancer disease. Neoplasia 11:956-963, 2009.

IF: 5,191

65. Fei F*, Yu Y*, Schmitt A, Rojewski MT, Chen B, Götz M, Guillaume P , Bunjes D, Schmitt

M. The inhibitory effect of cyclosporine A and prednisolone on both cytotoxic CD8 + T cells

and CD4 + CD25 + regulatory T cells. Current Signal Transduction Therapy 4:222-233, 2009.

IF: 0,769 (*both authors contributed equally)


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

66. Casalegno-Garduño R, Schmitt A, Yao J, Wang X, Xu X, Freund M, Schmitt M. Multimer

technologies for detection and adoptive transfer of antigen specific T cells. Cancer

Immunol Immunother, 2009, Oct 22 [Epub ahead of print]

IF: 3,804

67. Fei F*, Yu Y*, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Döhner H , Bunjes D,

Schmitt M. Effects of nilotinib on regulatory T cells: the dose matters. Mol Cancer, 2010

(in press) (*both authors contributed equally)

IF: 5,360

68. Greiner J*, Schmitt A*, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M,

Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M. High dose RHAMM-R3 peptide

vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome

(MDS) and multiple myeloma (MM). Haematologica, 2010 (in press) (*both authors

contributed equally)

IF: 5,516

69. Giannopoulos K, Dmoszynska A, Kowal M, Rolinski J, Gostick E, Price DA, Greiner J,

Rojewski MT, Stilgenbauer S, Döhner H, Schmitt M. Peptide vaccination elicits leukemia-

associated antigen-specific cytotoxic CD8+ T-cell responses with potential clinical

relevance in patients with chronic lymphocytic leukemia. Leukemia, 2010 (in press)

IF: 8,634


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

ÜBERSICHTSARBEITEN / REVIEWS

1. Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, Akiyoshi K, Sunamoto J,

Nakamura H. Development of a cancer vaccine: peptides, proteins, and DNA. Cancer

Chemother Pharmacol 46: S77-S82, 2000.

IF: 2,740

2. Schmitt M, J Greiner. Definition of immunogenic antigens in chronic myeloid leukemia

(CML) towards the development of cancer vaccines. Leuk Research 29: 1367-9, 2005.

IF: 2,390

3. Rasche M, Czock D, Keller F, Schmitt M. Chemotherapie und Dosierung der Zytostatika

bei Patienten mit Niereninsuffizienz insbesondere bei Dialysepflichtigkeit oder nach

Nierentransplantation. Mitteilung Klinische Nephrologie 35:11-20, 2006.

IF: not yet listed

4. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid

leukemia (AML) – Definition of Targets and current clinical protocols (review).

Haematologica 91:1653-1661, 2006.

IF: 5,516

5. Greiner J, Schmitt M. Cancer testis/germline antigens (CT/CG-antigens) in leukemias.

Leuk Res 31:1-3, 2007.

IF: 2,390

6. Guinn B, Mills KI, Czepulkowski B, Schmitt M, Greiner J. Leukaemia associated antigens

and their dual role as biomarkers and therapeutical targets for acute myeloid leukaemia.

Biomarker Insights 2:1-11, 2007.

IF: not yet listed

7. Schmitt A, Hus I, Schmitt M. Dendritic cell vaccines for patients with leukemias. Expert

Rev Anticancer Ther 7:275-283, 2007.

IF: 2,296

8. Greiner J, Schmitt M. Leukemia-Associated Antigens (LAAs) as target structures for a

specific immunotherapy in chronic myeloid leukemia (CML). Eur J Haematol 80:461-468,

2008.

IF: 2,237


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

9. Greiner J, Schmitt M. Current status of peptide vaccines for cancer immunotherapy in

malignant myeloid diseases. Memo 1:1-4, 2008.

IF: not yet listed

10. Schmitt A, Schmitt M. Dual attack on myeloblastic leukemic cells: the stimulus by B7

molecules matters. Leuk Lymphoma 50:315-316, 2009.

IF: 1,939

11. Schmitt M, Casalegno-Garduño R, Xu X, Schmitt A. Peptide vaccines for patients with

acute myeloid leukemia. Exp Rev Vaccines 8:1415-25, 2009.

IF: 2,900

SUMMARY

Impact Factor as a First/Last Author: 182,1

Overall Impact Factor: 298,4

Number of all Articles: 80

Number of Original Articles: 69

Number of Reviews: 11

Number of First/Last Authorships: 53

Number of Coauthorships: 27


Publikationsverzeichnis Prof. Dr. med. Michael Schmitt

Chronologisches Verzeichnis der Buchkapitel:

1. Keilholz U, Schmitt M, Scheibenbogen C, Bergmann L. Kap. 16.2. Zelluläre

Immuntherapie. In: Schmoll HJ, Höffken K, Possinger, K. Kompendium Internistische

Onkologie, 3. Ausg., Springer-Verlag, Heidelberg, ISBN 3-540-64398-2, pp. 1173-1181,

1999.

2. Schmitt M, Miyahara Y, Gu X, Mukae K, Satoh K, Nakayama E, Bergmann L, and Shiku

H. Differential enhancement of graft-versus-host (GVH) and graft-versus-leukemia (GVL)

reactions by interleukin-12 (IL-12). Molecular Biology of Hematopoiesis 6, (Eds.) Abraham,

Tabilio, Martelli, Asano, Donfransceso. Kluwer Academic/Plenum Publishers, New York,

ISBN 0-306-46136-6, pp. 83-89, 1999.

3. Greiner J, Ringhoffer M, Szmaragowska A, Hübsch S, Döhner H, Schmitt M. Quantitative

measurement of the mRNA expression of the tumor-associated antigen PRAME by real-

time RT-PCR using the LightCycler and SYBR green I technology. In: Rapid Cycle Real

Time PCR - Methods and Applications, Genetics and Oncology, (Eds.) Dietmaier, Wittwer,

Sivasubramanian. Springer-Verlag, Heidelberg, ISBN 3-540-42600-0, pp. 177-186, 2002.

4. Greiner J, Ringhoffer M, Taniguchi M, Döhner H and Schmitt M. Characterization of

leukemia-associated antigens in acute and chronic myeloid leukemias (AML/CML), 7th

Annual Meeting of the European Haematology Association - Free Papers (Florence, Italy,

June 6-9, 2002) Monduzzi Editore, Bologna, Italy. ISBN 88-323-2606-X, pp. 189-192,

2002.

5. Keilholz U, Bergmann L, Schmitt M, Scheibenbogen C. Kap. 15.2. Zelluläre

Immuntherapie. In: Schmoll HJ, Höffken K, Possinger K. Kompendium Internistische

Onkologie, 4. Ausg., Springer-Verlag, Heidelberg, pp. 707-713, 2005.

6. Greiner J, Schmitt M. T cell therapy for patients targeting leukemia-associated antigens

(LAAs) in haematological malignancies and after allogeneic stem cell transplantation. in:

New Insights in Hematopoietic Cell Transplantation, Editors: A. Spyridonidis and I.

Sakellari, 2010 (in press) ISBN: 978-81-308-0383-8.

Rostock, im Januar 2010

Prof. Dr. med. M. Schmitt

More magazines by this user
Similar magazines